(UroToday.com) The American Urologic Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Andrei Iagaru discussing the prospective evaluation of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer and the detection of extra-pelvic oligometastases. 18F-DCFPyl has been shown to have intense uptake in the bladder, kidneys, salivary glands, and lacrimal glands, with weak uptake in the liver, spleen, and bowel: